top of page

Visit the new TenaTac® website at 



Intra-operative bleeding can extend overall operative and anaesthetic time, potentially increasing both the risks of patient morbidity and mortality, and total healthcare costs. Haemostats are used to treat persistent bleeding from tissue beds or small blood vessels that cannot be treated effectively with conventional methods, while haemostatic sealants provide bleeding control and help to seal wounds.​ While standard haemostats (such as gelatin sponges) cost around €5-15 per dose, fibrin sealants in patch or liquid form can cost over €200 per dose. In addition to their high price, currently marketed products suffer from other problems which limit their widespread adoption. For example, some market leading products are unable to control stronger bleeds, while others contain blood-derived thrombin and fibrinogen.


Selentus has developed an innovative technology that enhances the adhesion of a conventional gelatine sponge to an area of surgical bleeding, ensuring that the product will remain in situ to maximise haemostatic control. This novel technology has the potential to reduce post-operative bleeding complications. Selentus’ technology is based upon a unique surface modification in which no new materials are added. Patents have been filed in all major territories and granted in the U.K. (GB 2543307), U.S.A. (US 10,653,821), Europe (EP 3362110), Japan (JP 6854825), Brazil (BR 112018007612-0 B1), China (CN 108136080 B) and India (497548), and pending in South Korea. A full-scale industrial process has been developed which can easily be integrated into an existing manufacturing facility. In addition to its lead product TenaTac®, Selentus is developing a pipeline of other products based on this unique technology that offer high performance, low cost manufacture and avoid the use of blood-derived materials. 

bottom of page